Cargando…

Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes

SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reas...

Descripción completa

Detalles Bibliográficos
Autores principales: Montaner-Angoiti, Esperanza, Marín-García, Pablo Jesús, Llobat, Lola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913421/
https://www.ncbi.nlm.nih.gov/pubmed/36766357
http://dx.doi.org/10.3390/ani13030468
_version_ 1784885423272624128
author Montaner-Angoiti, Esperanza
Marín-García, Pablo Jesús
Llobat, Lola
author_facet Montaner-Angoiti, Esperanza
Marín-García, Pablo Jesús
Llobat, Lola
author_sort Montaner-Angoiti, Esperanza
collection PubMed
description SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reason. This high resistance to anticancer drugs makes it necessary to search for other therapies and other therapeutic targets. In this sense, the epigenetic regulators of neoplasia could be a promising object of study in the search for new research advances. ABSTRACT: Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic.
format Online
Article
Text
id pubmed-9913421
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134212023-02-11 Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes Montaner-Angoiti, Esperanza Marín-García, Pablo Jesús Llobat, Lola Animals (Basel) Review SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reason. This high resistance to anticancer drugs makes it necessary to search for other therapies and other therapeutic targets. In this sense, the epigenetic regulators of neoplasia could be a promising object of study in the search for new research advances. ABSTRACT: Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic. MDPI 2023-01-29 /pmc/articles/PMC9913421/ /pubmed/36766357 http://dx.doi.org/10.3390/ani13030468 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Montaner-Angoiti, Esperanza
Marín-García, Pablo Jesús
Llobat, Lola
Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title_full Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title_fullStr Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title_full_unstemmed Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title_short Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
title_sort epigenetic alterations in canine malignant lymphoma: future and clinical outcomes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913421/
https://www.ncbi.nlm.nih.gov/pubmed/36766357
http://dx.doi.org/10.3390/ani13030468
work_keys_str_mv AT montanerangoitiesperanza epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes
AT maringarciapablojesus epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes
AT llobatlola epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes